ABSTRACT

Biologic drugs revolutionized in the treatment of many inflammatory rheumatological diseases. After the expiry of the patent of approved biologic drug, biosimilar drugs become available and market in the treatment of rheumatological diseases. In this article, besides the effectiveness and safety issues, Turkish Society for Rheumatology recommend about the definition, naming, interchangeability and extrapolation of the biosimilar drugs.